Time to read
Following the announcement this morning of detailed analysis of the phase III Thai HIV vaccine trial, Deborah Jack, Chief Executive of NAT, comments;
“The Thai trial is a milestone in the search for a vaccine against HIV. Detailed analysis shows that the benefit was modest and primarily in the heterosexual community. However, it remains the case that this was the first ever vaccine candidate to show protection in humans.
These results are an incredible opportunity for scientists to discover new clues about HIV and learn how a HIV vaccine could work in practise. These lessons will be used to advance new vaccine candidates that are already in the development pipeline.
Today work to get treatment to people with HIV is vital, but we also have a responsibility to future generations to continue investing in developing an effective vaccine that will end the HIV pandemic.”